Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 19181901 | METHODS AND SYSTEMS FOR DETECTING A PRIMARY DISEASE | April 2025 | September 2025 | Allow | 5 | 1 | 0 | Yes | No |
| 19035409 | MYC AMPLIFICATION DRIVES RESISTANCE TO PAN-RAS INHIBITORS IN PANCREATIC CANCER | January 2025 | February 2026 | Allow | 13 | 1 | 1 | No | No |
| 18953769 | BIOMARKERS AND USES THEREFOR | November 2024 | January 2026 | Allow | 14 | 2 | 1 | No | No |
| 18821044 | METHODS FOR ENRICHING A TARGET POLYNUCLEOTIDE IN A SAMPLE | August 2024 | March 2025 | Allow | 6 | 1 | 0 | Yes | No |
| 18812678 | METHODS OF TREATING PSORIASIS | August 2024 | January 2026 | Allow | 17 | 2 | 1 | No | No |
| 18803351 | IDENTIFICATION AND USE OF CIRCULATING NUCLEIC ACID TUMOR MARKERS | August 2024 | April 2025 | Allow | 8 | 1 | 1 | Yes | No |
| 18752771 | GENE SIGNATURES FOR CANCER CHARACTERIZATION AND TREATMENT | June 2024 | October 2025 | Allow | 16 | 1 | 1 | No | No |
| 18665479 | ENRICHMENT OF CIRCULATING TUMOR DNA | May 2024 | May 2025 | Allow | 12 | 3 | 0 | Yes | No |
| 18640645 | METHODS OF DETECTING SPATIAL HETEROGENEITY OF A BIOLOGICAL SAMPLE | April 2024 | June 2025 | Allow | 14 | 1 | 1 | No | No |
| 18633462 | METHODS OF PREPARING A DNA FRACTION ENRICHED WITH CIRCULATING TUMOR DNA | April 2024 | October 2024 | Allow | 6 | 2 | 0 | Yes | No |
| 18625354 | COMPOSITIONS AND METHODS FOR DETECTION OF VIRAL PATHOGENS IN SAMPLES | April 2024 | March 2026 | Allow | 23 | 2 | 1 | Yes | No |
| 18429449 | Application of Feature Gene TRIM22 in Preparation of Reagent Regulating Expression of Breast Cancer-Related Gene | February 2024 | March 2025 | Abandon | 14 | 2 | 0 | No | No |
| 18410950 | PERSONALIZED METHODS FOR DETECTING CIRCULATING TUMOR DNA | January 2024 | January 2026 | Abandon | 24 | 4 | 0 | Yes | Yes |
| 18399181 | SINGLE-NUCLEOTIDE POLYMORPHISM LOCUS SIGNIFICANTLY RELATED TO YARDLONG BEAN ANTHOCYANIN CONTENT, KOMPETITIVE ALLELE-SPECIFIC POLYMERASE CHAIN REACTION MARKERS AND APPLICATION THEREOF | December 2023 | January 2026 | Allow | 25 | 1 | 0 | Yes | No |
| 18394161 | GENOMIC ALTERATIONS IN THE TUMOR AND CIRCULATION OF PANCREATIC CANCER PATIENTS | December 2023 | October 2025 | Allow | 22 | 1 | 1 | Yes | No |
| 18391117 | MULTIPLEXED FUEL ANALYSIS | December 2023 | June 2025 | Allow | 18 | 0 | 0 | No | No |
| 18521390 | THERAPEUTIC AND DIAGNOSTIC METHODS FOR MAST CELL-MEDIATED INFLAMMATORY DISEASES | November 2023 | March 2025 | Abandon | 15 | 0 | 1 | No | No |
| 18385099 | SYSTEM FOR DETECTING AND CHARACTERIZING A MICROORGANISM | October 2023 | February 2026 | Allow | 28 | 1 | 0 | No | No |
| 18464360 | C-RAF Mutants that Confer Resistance to RAF Inhibitors | September 2023 | August 2024 | Allow | 11 | 2 | 1 | Yes | No |
| 18457040 | METHOD FOR DETERMINATION OF CELLULAR MRNA | August 2023 | July 2025 | Allow | 23 | 1 | 1 | No | No |
| 18451574 | METHOD OF DIAGNOSIS, STAGING AND MONITORING OF MELANOMA USING MICRORNA GENE EXPRESSION | August 2023 | August 2025 | Allow | 24 | 2 | 1 | No | No |
| 18450103 | CIRCULATING SERUM CELL-FREE DNA BIOMARKERS AND METHODS | August 2023 | July 2024 | Allow | 11 | 0 | 1 | No | No |
| 18349807 | KIT FOR DIAGNOSING GASTRIC CANCER USING miRNA EXPRESSION | July 2023 | January 2025 | Abandon | 18 | 1 | 0 | No | No |
| 18332781 | ANALYTICAL METHODS FOR CELL FREE NUCLEIC ACIDS AND APPLICATIONS | June 2023 | January 2025 | Abandon | 20 | 0 | 1 | No | No |
| 18330112 | METHODS AND COMPOSITIONS FOR PREDICTION OF THERAPEUTIC EFFICACY OF CANCER TREATMENTS AND CANCER PROGNOSIS | June 2023 | August 2024 | Allow | 15 | 1 | 1 | No | No |
| 18325500 | Inhibition Of HSD17B13 In The Treatment Of Liver Disease In Patients Expressing The PNPLA3 I148M Variation | May 2023 | December 2024 | Allow | 19 | 2 | 0 | Yes | No |
| 18141862 | EML4-ALK TRANSLOCATIONS IN LUNG CANCER | May 2023 | January 2025 | Allow | 21 | 2 | 1 | Yes | No |
| 18307093 | NON-INVASIVE FETAL GENETIC SCREENING BY DIGTAL ANALYSIS | April 2023 | February 2026 | Abandon | 33 | 2 | 0 | No | Yes |
| 18298777 | Methods for Quantification of Nucleosome Modifications and Mutations at Genomic Loci and Clinical Applications Thereof | April 2023 | February 2025 | Abandon | 23 | 1 | 1 | No | No |
| 18025639 | USE OF microRNA (miRNA) MARKER IN PREPARATION OF PRODUCT FOR EVALUATING THERAPEUTIC EFFECT OF OLANZAPINE IN TREATMENT OF SCHIZOPHRENIA (SZ) AND KIT | March 2023 | July 2024 | Allow | 16 | 1 | 0 | Yes | No |
| 18179825 | ASSOCIATION OF RARE RECURRENT GENETIC VARIATIONS TO ATTENTION-DEFICIT, HYPERACTIVITY DISORDER (ADHD) AND METHODS OF USE THEREOF FOR THE DIAGNOSIS AND TREATMENT OF THE SAME | March 2023 | November 2024 | Abandon | 21 | 1 | 1 | No | No |
| 18010459 | COMPOSITION FOR DIAGNOSING OR TREATING KIDNEY DISEASE | December 2022 | February 2026 | Allow | 38 | 1 | 1 | Yes | No |
| 18063015 | METHODS OF TREATING TUMOR | December 2022 | December 2024 | Abandon | 25 | 2 | 1 | No | No |
| 17994894 | Biomarkers for the Diagnosis of Parkinson's Disease | November 2022 | June 2025 | Abandon | 30 | 4 | 1 | Yes | No |
| 17987424 | METHODS AND COMPOSITIONS FOR INHIBITING AND TREATING NEUROLOGICAL CONDITIONS | November 2022 | May 2025 | Abandon | 30 | 1 | 0 | No | No |
| 17924791 | BIOMARKERS FOR PREDICTING OVERALL SURVIVAL IN RECORRENT/METASTATIC HEAD AND NECK SQUAMOUS CELL CARCINOMA | November 2022 | February 2026 | Abandon | 39 | 0 | 1 | No | No |
| 18046354 | ARC-BASED CAPSIDS AND USES THEREOF | October 2022 | January 2026 | Allow | 39 | 1 | 0 | No | No |
| 17914218 | METHODS AND TOOLS FOR ANALYSING THE DUCHENNE MUSCULAR DYSTROPHY (DMD) GENE | September 2022 | January 2026 | Abandon | 40 | 0 | 1 | No | No |
| 17757317 | BIOMARKERS AND USES THEREOF IN THE TREATMENT OF CHRONIC HEPATITIS B INFECTION | June 2022 | November 2025 | Abandon | 41 | 0 | 1 | No | No |
| 17831345 | METHOD OF TREATING A CANCER PATIENT WITHOUT THE NEED FOR A TISSUE BIOPSY | June 2022 | September 2024 | Allow | 28 | 2 | 1 | Yes | No |
| 17826834 | Digital Analysis of Blood Samples to Determine Efficacy of Cancer Therapies for Specific Cancers | May 2022 | February 2025 | Allow | 33 | 3 | 1 | No | No |
| 17678829 | METHODS OF DETECTING DNA IN A SAMPLE | February 2022 | January 2025 | Allow | 35 | 2 | 1 | No | No |
| 17667781 | CRENOLANIB FOR TREATING FLT3 MUTATED PROLIFERATIVE DISORDERS ASSOCIATED MUTATIONS | February 2022 | February 2026 | Allow | 48 | 1 | 1 | Yes | No |
| 17588196 | METHODS AND KITS TO IDENTIFY KLEBSIELLA STRAINS | January 2022 | September 2024 | Allow | 32 | 2 | 1 | No | No |
| 17619599 | XYLANASE MUTANT HAVING IMPROVED SPECIFIC ACTIVITY | December 2021 | November 2025 | Allow | 47 | 2 | 1 | Yes | No |
| 17551113 | Biomarkers for the Diagnosis of Lung Cancers | December 2021 | April 2025 | Abandon | 40 | 2 | 1 | Yes | No |
| 17611603 | METHOD FOR DETECTING EXTRACELLUAR VESICLES | November 2021 | March 2026 | Abandon | 52 | 2 | 1 | No | No |
| 17521333 | USING NUCLEIC ACID SIZE RANGE FOR NONINVASIVE CANCER DETECTION | November 2021 | November 2024 | Allow | 36 | 3 | 1 | Yes | No |
| 17607200 | Broad-Spectrum Nanoparticle Enabled Genomic Detection | October 2021 | October 2025 | Allow | 47 | 2 | 1 | Yes | No |
| 17606099 | METHOD FOR PREDICTING THE RESPONSE OF ANTIPSYCHOTIC DRUGS | October 2021 | May 2025 | Abandon | 43 | 0 | 1 | No | No |
| 17451482 | TREATMENT OF CANCER BY RISK STRATIFICATION OF PATIENTS BASED ON COMORDIDITIES | October 2021 | October 2024 | Abandon | 36 | 1 | 1 | Yes | No |
| 17499060 | ALZHEIMER'S DISEASE PERSONALIZED MEDICINE | October 2021 | October 2025 | Abandon | 48 | 0 | 1 | No | No |
| 17493826 | DETECTING CANCER RISK | October 2021 | November 2025 | Allow | 49 | 5 | 1 | Yes | No |
| 17491237 | DRAIN FLUID FOR DIAGNOSTICS | September 2021 | October 2024 | Allow | 36 | 5 | 1 | Yes | No |
| 17480839 | RNA Printing and Sequencing Devices, Methods, and Systems | September 2021 | February 2026 | Allow | 53 | 1 | 1 | No | No |
| 17479701 | Methods and Compositions For Identifying And Treating Patients With Small Cell Lung Cancer | September 2021 | August 2024 | Allow | 35 | 2 | 1 | No | No |
| 17471914 | Salivary Extracellular Rna Biomarkers for Gingivitis | September 2021 | October 2024 | Abandon | 37 | 2 | 1 | No | Yes |
| 17461298 | METHODS FOR CANCER DETECTION AND MONITORING | August 2021 | April 2025 | Allow | 44 | 4 | 0 | Yes | No |
| 17429997 | BIOMARKER PANEL FOR DIAGNOSIS AND PROGNOSIS OF CANCER | August 2021 | April 2025 | Abandon | 44 | 0 | 1 | No | No |
| 17429357 | DIRECT CARBAPENEMASE TRIPLE (KPC-2, OXA-48, NDM-1) PCR DIAGNOSTIC KIT | August 2021 | April 2025 | Abandon | 44 | 1 | 1 | No | No |
| 17426576 | Treatment of Atopic Dermatitis Using Mesenchymal Stem Cells and Immune Modulation | July 2021 | November 2025 | Abandon | 51 | 2 | 1 | Yes | No |
| 17385568 | METHOD FOR THE DIAGNOSIS, PROGNOSIS AND TREATMENT OF BREAST CANCER METASTASIS | July 2021 | January 2025 | Allow | 42 | 3 | 1 | Yes | No |
| 17425228 | METHODS AND COMPOSITIONS FOR DETECTING TRANSFUSION-TRANSMITTED PATHOGENS | July 2021 | April 2025 | Allow | 45 | 1 | 1 | Yes | No |
| 17378487 | ALZHEIMER'S DISEASE PERSONALIZED MEDICINE | July 2021 | April 2025 | Allow | 45 | 2 | 1 | Yes | No |
| 17370646 | METHODS FOR NON-INVASIVE DETECTION OF TRANSPLANT HEALTH OR REJECTION | July 2021 | September 2025 | Abandon | 50 | 1 | 0 | No | No |
| 17420602 | SYSTEMS AND METHODS FOR CHARACTERIZING AND TREATING DISEASE | July 2021 | March 2026 | Allow | 56 | 4 | 1 | Yes | No |
| 17363897 | GENOTYPE-DIRECTED LOCAL DELIVERY OF TARGETED THERAPEUTICS | June 2021 | February 2026 | Abandon | 56 | 1 | 1 | No | No |
| 17417811 | MICROFLUIDIC SAMPLE LABELING | June 2021 | February 2025 | Abandon | 44 | 0 | 1 | No | No |
| 17355468 | Crenolanib for Treating FLT3 Mutated Proliferative Disorders Associated Mutations | June 2021 | May 2025 | Allow | 47 | 3 | 1 | Yes | No |
| 17416681 | METHODS FOR RNA ANALYSIS | June 2021 | April 2025 | Allow | 46 | 1 | 1 | No | No |
| 17413480 | MARKERS OF DISEASE PROGNOSIS IN MULTIPLE SCLEROSIS | June 2021 | June 2025 | Allow | 48 | 2 | 1 | No | No |
| 17413275 | IN-VITRO METHOD FOR DIAGNOSIS AND PROGNOSIS OF A DISEASE | June 2021 | October 2025 | Abandon | 52 | 1 | 1 | No | No |
| 17298863 | METHOD FOR DETERMINING PROGNOSIS OF ENDOMETRIAL CANCER | June 2021 | November 2024 | Abandon | 41 | 0 | 1 | No | No |
| 17323429 | METHODS FOR SUBTYPING OF LUNG SQUAMOUS CELL CARCINOMA | May 2021 | July 2024 | Allow | 38 | 3 | 1 | No | No |
| 17314442 | METHOD FOR IDENTIFYING CANCER IN A SUBJECT | May 2021 | January 2026 | Allow | 57 | 4 | 1 | Yes | No |
| 17234250 | CRENOLANIB FOR TREATING FLT3 MUTATED PROLIFERATIVE DISORDERS ASSOCIATED MUTATIONS | April 2021 | September 2025 | Allow | 53 | 4 | 1 | Yes | No |
| 17226007 | System and Method for Tracking Infectious Disease | April 2021 | December 2024 | Abandon | 44 | 0 | 1 | No | No |
| 17214695 | NOVEL GENE CLASSIFIERS AND USES THEREOF IN PSORIASIS | March 2021 | March 2025 | Abandon | 48 | 8 | 1 | No | No |
| 17274154 | METHODS OF USING GENETIC MARKERS ASSOCIATED WITH ENDOMETRIOSIS | March 2021 | December 2024 | Abandon | 45 | 0 | 1 | No | No |
| 17274019 | LONG NON-CODING RNAS (LNCRNAS) FOR THE DIAGNOSIS AND THERAPEUTICS OF BRAIN DISORDERS, IN PARTICULAR COGNITIVE DISORDERS | March 2021 | February 2025 | Allow | 48 | 2 | 1 | No | No |
| 17273568 | PRE-SURGICAL RISK STRATIFICATION BASED ON PDE4D7 AND DHX9 EXPRESSION | March 2021 | September 2024 | Allow | 42 | 1 | 1 | No | No |
| 17183273 | MICRORNA-134 BIOMARKER | February 2021 | April 2025 | Allow | 50 | 2 | 1 | No | No |
| 17266951 | MULTIPLEX DETECTION OF NUCLEIC ACIDS | February 2021 | July 2024 | Allow | 41 | 1 | 0 | No | No |
| 17264217 | MOLECULAR ASSESSMENT OF TRBC USAGE | January 2021 | October 2024 | Allow | 45 | 2 | 1 | No | No |
| 17263979 | PAPER-BASED, NUCLEIC ACID-DETECTING KIT AND METHOD FOR ANALYSIS OF PCR AMPLICON | January 2021 | October 2025 | Allow | 57 | 4 | 1 | Yes | No |
| 17156024 | METHODS FOR SUBTYPING OF LUNG ADENOCARCINOMA | January 2021 | July 2024 | Allow | 42 | 3 | 1 | No | No |
| 17258434 | Multiplexed Fuel Analysis | January 2021 | April 2025 | Allow | 51 | 2 | 1 | Yes | No |
| 17256659 | METHOD FOR IDENTIFYING AND EVALUATING TOXIGENIC CAPABILITY OF AFLATOXIGENIC STRAIN | December 2020 | March 2025 | Allow | 51 | 2 | 1 | Yes | No |
| 17253571 | GASTRIC CANCER BIOMARKER AND USE THEREOF | December 2020 | November 2024 | Abandon | 47 | 2 | 1 | No | No |
| 17058550 | METHODS FOR WATERMARKING AND IDENTIFYING CHEMICAL COMPOSITIONS | November 2020 | May 2025 | Abandon | 54 | 2 | 1 | No | No |
| 16970697 | METHOD FOR DISCRIMINATING SEX OF YELLOWTAIL GROUP | October 2020 | August 2024 | Allow | 48 | 1 | 1 | No | No |
| 17010912 | SIGNATURES AND DETERMINANTS FOR DISTINGUISHING BETWEEN A BACTERIAL AND VIRAL INFECTION AND METHODS OF USE THEREOF | September 2020 | November 2024 | Abandon | 50 | 1 | 1 | No | No |
| 16956215 | Method for Treatment of Hypertension | June 2020 | February 2025 | Allow | 59 | 2 | 1 | No | No |
| 16874473 | NOVEL GENE CLASSIFIERS AND USES THEREOF IN AUTOIMMUNE DISEASES | May 2020 | September 2025 | Abandon | 60 | 10 | 1 | Yes | No |
| 16754042 | DETECTION OF METASTATIC DISEASE AND RELATED METHODS | April 2020 | July 2025 | Allow | 60 | 4 | 2 | Yes | No |
| 16651863 | DIGITAL NUCLEASE DETECTION COMPOSITIONS AND METHODS | March 2020 | April 2025 | Allow | 60 | 2 | 1 | Yes | No |
| 16613114 | UNIVERSAL EARLY CANCER DIAGNOSTICS | November 2019 | September 2024 | Allow | 60 | 4 | 2 | Yes | Yes |
| 16498581 | METHODS OF USING GIANT CELL NUCLEIC ACID CHARACTERIZATION IN CANCER SCREENING, DIAGNOSTICS, TREATMENT AND RECURRENCE | September 2019 | August 2025 | Allow | 60 | 5 | 1 | No | No |
| 16494500 | METHODS AND PROCESSES FOR ASSESSMENT OF GENETIC MOSAICISM | September 2019 | July 2025 | Allow | 60 | 4 | 1 | Yes | No |
| 16295536 | METHODS FOR DIAGNOSING AND TREATING INFLAMMATORY BOWEL DISEASE | March 2019 | January 2020 | Allow | 10 | 1 | 0 | No | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner MYERS, CARLA J.
With a 0.0% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is in the bottom 25% across the USPTO, indicating that appeals face significant challenges here.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 39.3% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is above the USPTO average, suggesting that filing an appeal can be an effective strategy for prompting reconsideration.
⚠ Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.
✓ Filing a Notice of Appeal is strategically valuable. The act of filing often prompts favorable reconsideration during the mandatory appeal conference.
Examiner MYERS, CARLA J works in Art Unit 1682 and has examined 252 patent applications in our dataset. With an allowance rate of 91.3%, this examiner allows applications at a higher rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 39 months.
Examiner MYERS, CARLA J's allowance rate of 91.3% places them in the 76% percentile among all USPTO examiners. This examiner is more likely to allow applications than most examiners at the USPTO.
On average, applications examined by MYERS, CARLA J receive 2.23 office actions before reaching final disposition. This places the examiner in the 61% percentile for office actions issued. This examiner issues a slightly above-average number of office actions.
The median time to disposition (half-life) for applications examined by MYERS, CARLA J is 39 months. This places the examiner in the 25% percentile for prosecution speed. Prosecution timelines are slightly slower than average with this examiner.
Conducting an examiner interview provides a +15.0% benefit to allowance rate for applications examined by MYERS, CARLA J. This interview benefit is in the 54% percentile among all examiners. Recommendation: Interviews provide an above-average benefit with this examiner and are worth considering.
When applicants file an RCE with this examiner, 29.5% of applications are subsequently allowed. This success rate is in the 56% percentile among all examiners. Strategic Insight: RCEs show above-average effectiveness with this examiner. Consider whether your amendments or new arguments are strong enough to warrant an RCE versus filing a continuation.
This examiner enters after-final amendments leading to allowance in 60.6% of cases where such amendments are filed. This entry rate is in the 86% percentile among all examiners. Strategic Recommendation: This examiner is highly receptive to after-final amendments compared to other examiners. Per MPEP § 714.12, after-final amendments may be entered "under justifiable circumstances." Consider filing after-final amendments with a clear showing of allowability rather than immediately filing an RCE, as this examiner frequently enters such amendments.
When applicants request a pre-appeal conference (PAC) with this examiner, 200.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 93% percentile among all examiners. Strategic Recommendation: Pre-appeal conferences are highly effective with this examiner compared to others. Before filing a full appeal brief, strongly consider requesting a PAC. The PAC provides an opportunity for the examiner and supervisory personnel to reconsider the rejection before the case proceeds to the PTAB.
This examiner withdraws rejections or reopens prosecution in 96.2% of appeals filed. This is in the 85% percentile among all examiners. Of these withdrawals, 88.0% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner frequently reconsiders rejections during the appeal process compared to other examiners. Per MPEP § 1207.01, all appeals must go through a mandatory appeal conference. Filing a Notice of Appeal may prompt favorable reconsideration even before you file an Appeal Brief.
When applicants file petitions regarding this examiner's actions, 48.4% are granted (fully or in part). This grant rate is in the 44% percentile among all examiners. Strategic Note: Petitions show below-average success regarding this examiner's actions. Ensure you have a strong procedural basis before filing.
Examiner's Amendments: This examiner makes examiner's amendments in 26.2% of allowed cases (in the 99% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.9% of allowed cases (in the 59% percentile). This examiner issues Quayle actions more often than average when claims are allowable but formal matters remain (MPEP § 714.14).
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.